- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2191-1991
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Pharmaceutical regulation in Europe and its impact on corporate R&D ; volume:4 ; number:1 ; day:3 ; month:10 ; year:2014 ; pages:1-9 ; date:12.2014
Health economics review ; 4, Heft 1 (3.10.2014), 1-9, 12.2014
- Klassifikation
-
Wirtschaft
- Urheber
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s13561-014-0023-5
- URN
-
urn:nbn:de:101:1-2019102914494867789123
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
- 15.08.2025, 07:36 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Eger, Stephan
- Mahlich, Jörg C.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Pharmaceutical regulation in Europe and its impact on corporate R&D
Revisiting the Relationship Between Price Regulation and Pharmaceutical R&D Investment
Revisiting the Relationship Between Price Regulation and Pharmaceutical R&D Investment
Corporate R&D and firm efficiency: evidence from Europe's top R&D investors
Corporate R&D and firm efficiency: Evidence from Europe’s top R&D investors
Does Europe perform too little corporate R&D? A comparison of EU and non-EU corporate R&D performance
R&D in the Belgian Pharmaceutical Sector
Pharmaceutical patents: incentives for R&D or marketing?
R&D Spin-outs in the pharmaceutical industry
Pharmaceutical regulation and health policy objectives
Changing R&D models in research-based pharmaceutical companies
Innovation in pharmaceutical R&D: mapping the research landscape
Pharmaceutical regulation in Europe and its impact on corporate R&D
Revisiting the Relationship Between Price Regulation and Pharmaceutical R&D Investment
Revisiting the Relationship Between Price Regulation and Pharmaceutical R&D Investment
Corporate R&D and firm efficiency: evidence from Europe's top R&D investors
Corporate R&D and firm efficiency: Evidence from Europe’s top R&D investors
Does Europe perform too little corporate R&D? A comparison of EU and non-EU corporate R&D performance
R&D in the Belgian Pharmaceutical Sector
Pharmaceutical patents: incentives for R&D or marketing?
R&D Spin-outs in the pharmaceutical industry
Pharmaceutical regulation and health policy objectives
Changing R&D models in research-based pharmaceutical companies
Innovation in pharmaceutical R&D: mapping the research landscape
Pharmaceutical regulation in Europe and its impact on corporate R&D
Revisiting the Relationship Between Price Regulation and Pharmaceutical R&D Investment
Revisiting the Relationship Between Price Regulation and Pharmaceutical R&D Investment
Corporate R&D and firm efficiency: evidence from Europe's top R&D investors
Corporate R&D and firm efficiency: Evidence from Europe’s top R&D investors
Does Europe perform too little corporate R&D? A comparison of EU and non-EU corporate R&D performance
R&D in the Belgian Pharmaceutical Sector
Pharmaceutical patents: incentives for R&D or marketing?
R&D Spin-outs in the pharmaceutical industry
Pharmaceutical regulation and health policy objectives
Changing R&D models in research-based pharmaceutical companies